500672 NOVARTIND

Novartis India Share Price

 

 

Start SIP in NOVARTIND

Start SIP
Novartis India live price: ₹1014. It opened at ₹965 vs previous close ₹971; intraday high/low: ₹1,029/₹965. The 50 & 200 DMA stand at ₹896.30/₹880.29.

Novartis India Performance

  • Today's Low
  • ₹965
  • Today's High
  • ₹1,029
  • 52 Week Low
  • ₹748
  • 52 Week High
  • ₹1,100
  • Open Price₹965
  • Previous Close₹971
  • Volume44,678
  • 50 DMA₹896.30
  • 100 DMA₹874.40
  • 200 DMA₹880.29

Investment Returns

  • Over 1 Month + 11.28%
  • Over 3 Month + 30.17%
  • Over 6 Month + 15.85%
  • Over 1 Year + 29.16%

Smart Investing Starts Here Start SIP with Novartis India for Steady Growth!

Invest Now

Novartis India Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 25.7
  • PEG Ratio
  • 2
  • Market Cap Cr
  • 2,504
  • P/B Ratio
  • 3.2
  • Average True Range
  • 34.69
  • EPS
  • -
  • Dividend Yield
  • 2.5
  • MACD Signal
  • 21.44
  • RSI
  • 68.85
  • MFI
  • 62.69

Novartis India Financials

Novartis India Technicals

EMA & SMA

Current Price
₹1,014.00
+ 43.2 (4.45%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹938.22
  • 50 Day
  • ₹896.30
  • 100 Day
  • ₹874.40
  • 200 Day
  • ₹880.29

Resistance and Support

1002.5 Pivot Speed
  • R3 1,104.10
  • R2 1,066.40
  • R1 1,040.20
  • S1 976.30
  • S2 938.60
  • S3 912.40

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Novartis is a global healthcare company based in Switzerland, specializing in innovative pharmaceuticals and generics. The company focuses on research and development to deliver effective treatments across various therapeutic areas, including oncology, cardiology, and neuroscience, improving patient outcomes worldwide.

Novartis India has an operating revenue of Rs. 347.66 Cr. on a trailing 12-month basis. An annual revenue de-growth of 0% needs improvement, Pre-tax margin of 37% is great, ROE of 12% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. It is currently FORMING a base in its weekly chart and is trading around 9% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 60 which is a FAIR score but needs to improve its earnings, a RS Rating of 87 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 37 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Novartis India Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-01-28 Quarterly Results
2025-10-28 Quarterly Results
2025-07-29 Quarterly Results
2025-05-09 Audited Results & Final Dividend
2025-01-28 Quarterly Results
Date Purpose Remarks
2025-07-23 FINAL Rs.25.00 per share(500%)Final Dividend
View Novartis India Dividend History Arrow

Novartis India F&O

Novartis India Shareholding Pattern

70.68%
0%
0.51%
0.19%
0.01%
22.67%
5.94%

Novartis India FAQs

Novartis India share price is ₹1,014 As on 01 April, 2026 | 20:13

The Market Cap of Novartis India is ₹2503.6 Cr As on 01 April, 2026 | 20:13

The P/E ratio of Novartis India is 25.7 As on 01 April, 2026 | 20:13

The PB ratio of Novartis India is 3.2 As on 01 April, 2026 | 20:13

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23